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Immunodominance of an Antiviral Cytotoxic T Cell Response
Is Shaped by the Kinetics of Viral Protein Expression1
Hans Christian Probst,* Kathrin Tschannen,* Awen Gallimore,2† Marianne Martinic,*
Michael Basler,‡ Tilman Dumrese,* Emma Jones,† and Maries F. van den Broek3*
Lymphocytic choriomeningitis virus (LCMV) infection induces a protective CTL response consisting of gp- and nucleoprotein
(NP)-specific CTL. We find that a small load of LCMV led to immunodominance of NP-CTL, whereas a large viral load resulted
in dominance of gp-CTL. This is the first study describing that immunodominance is not fixed after infection with a given
pathogen, but varies with the viral load instead. We assumed higher Ag sensitivity for NP-CTL, which would explain their
preferential priming at low viral load, as well as their overstimulation resulting in selective exhaustion at high viral load. The
higher Ag sensitivity of NP-CTL was due to faster kinetics of NP-epitope presentation. Thus, we uncover a novel factor that
impinges upon immunodominance and is related to the kinetics of virus protein expression. We propose that CTL against early
viral proteins swiftly interfere with virus replication, resulting in efficient protection. If these “early” CTL fail in immediate virus
control, they are activated in the face of higher viral load compared with “late” CTL and are therefore prone to be exhausted.
Thus, the observed absence of early CTL in persistent infections might not be the cause, but rather the consequence of viral
persistence. The Journal of Immunology, 2003, 171: 5415–5422.
T he CD8 CTL recognize peptides presented by MHCclass I molecules on the surface of APC (1). These pep-tides are predominantly generated from endogenous pro-
teins in a proteasome- and TAP-dependent fashion (2–4). Viral
peptides will therefore be presented on infected cells by MHC
class I molecules, and as a result, virus-specific CTL are important
effectors to control virus replication and spread (5–9).
Infection of C57BL/6 (H-2b) mice with lymphocytic choriomen-
ingitis virus (LCMV)5 induces a strong and protective CTL re-
sponse that is dominated by four epitopes: gp-derived gp33–41/
Db, gp34–41/Kb, and gp276–286/Db and nucleoprotein (NP)-
derived NP396–404/Db. The response in BALB/c (H-2d) mice is
strongly dominated by NP118–126/Ld, but also responses to
gp283–292/Kd are detectable (10–17). After infection with
LCMV-Armstrong (Arm), the CTL response in C57BL/6 mice is
dominated by NP396-CTL (15, 17), whereas infection of mice
with faster replicating strains such as LCMV-WE, LCMV-Docile
(Doc), or LCMV-Arm Clone13 or -t1b (18) results in immu-
nodominance of gp33-CTL (10, 18, 19).
Preferential priming of NP396-CTL at low virus load and im-
munodominance of gp33-CTL at high virus load suggest that
NP396-CTL are more sensitive to Ag in some way and selective
exhaustion (18, 20, 21) of NP396-CTL may explain their gradual
disappearance upon increasing viral load. Several studies de-
scribed the association between decreased CTL responses and high
viral load and disease progression in HIV infection (22–24) or
infection with LCMV (20). Exhaustion of specific CTL in persis-
tent infections is facilitated in the absence of CD4 cells (18,
25–27), but can also happen in the presence of fully functional
CD4 cells (21).
We have performed experiments to delineate the relationship
among virus burden, immunodominance, and protection against
persistent infection. Other studies have previously identified dif-
ferences in Ag processing, T cell repertoires, and MHC/peptide/
TCR avidities as important factors in controlling immunodomi-
nance. It was, however, clear from our early experiments that
neither of these factors could account for the shifting pattern of
immunodominance observed following infection of mice with vi-
ruses of different replicative capacities. In fibroblasts that were
infected with LCMV in vitro, the NP was detected substantially
before gp by immunoprecipitation (28). In this study, we show that
this kinetic difference in protein production has consequences for
LCMV-derived Ag processing and presentation: LCMV-infected
cells presented NP-derived CTL epitopes 8 h before they presented
gp-derived epitopes. NP-CTL indeed seemed to interact with
LCMV-infected cells in vivo before gp-CTL, as we show that
priming of gp-CTL in vivo was prevented by the presence of NP-
CTL, but not vice versa. In addition, we show that selective ex-
pansion of NP-CTL at low viral load is a feature intrinsic to
LCMV, as it did not occur after infection with recombinant vac-
cinia virus carrying LCMV CTL epitopes.
We propose that the kinetic difference in Ag presentation ex-
plains the preferential priming of NP-CTL at low viral load, their
selective exhaustion at high viral load, as well as their relatively
high protective capacity in vivo (19). Thus, we discovered a novel
factor that impinges on immunodominance and which is related to
the kinetics of Ag presentation.
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Materials and Methods
Mice
C57BL/6 (H-2b) and BALB/c (H-2d) mice were bred in the Institut fu¨r
Labortierkunde, University of Zurich (Zurich, Switzerland). 318 TCR-
transgenic mice expressing the P14 TCR that is specific for LCMV gp33–
41/Db are on a C57BL/6 background (29). CB6F1 (H-2bxd) were obtained
from Charles River Breeding Laboratories (Hannover, Germany). DIETER
mice have a pure C57BL/6 background and expression of gp33–41 and
NP396–404 as a transgene can be induced in their dendritic cells (DC)
(30). All mice were kept under specific pathogen-free conditions and were
at least 6 wk old at the beginning of the experiments. Animal experiments
were performed in compliance with Swiss national and cantonal laws
(Kantonales Veterina¨ramt Zu¨rich) on animal protection.
Viruses
LCMV-WE was originally obtained from Dr. F. Lehmann-Grube (Heinrich
Pette Institute, Hamburg, Germany) (31), LCMV-Arm was obtained from
Dr. M. Oldstone (The Scripps Clinic and Research Foundation, La Jolla,
CA) (32) and LCMV-Doc was a variant isolated from a LCMV-WE carrier
mouse and was obtained from C. Pfau (Department of Biology, Rensselaer
Polytechnic Institute, Washington, DC) (33). LCMV was propagated on
L929 cells at a low multiplicity of infection (m.o.i.). Vaccinia virus (VV),
strain WR, was originally obtained from Dr. B. Moss (National Institutes
of Health, Bethesda, MD). rVV carrying one of the two immunodominant
CTL epitopes of LCMV in the context of H-2b were generated by cloning
synthetic oligonucleotides encoding for the peptide sequence (5-CATG-
xxx-xxx-xxx-TA-3 and 5-CTAGAT-xxx-xxx-xxx-3, where xxx repre-
sents the peptide coding sequence and the underlined sequence the added
start codon) into the NcoI/BglII-digested transfer vector pSC11.3OR2 (34).
The minigene sequences were: gp33  AAAGCTGTGTACAATTTCGC
CACCTGT (MKAVYNFATC) and NP396  TTTCAACCACAAAAT
GGGCAATTCATA (MFQPQNGQFI). Recombinant viruses were selected
using 5-bromo-2-deoxyuridine and recombinant plaques were identified
by -galactosidase activity as described elsewhere (35). rVV were plaque
purified three times on BSC40 cells. As a control, VV expressing the
vesicular stomatitis virus gp (VVc) was used. All VV were propagated at
a low m.o.i. on BSC40 cells.
Dendritic cells
Bone marrow-derived DC were generated from the femora and tibiae of
DIETER mice as previously described (36). Mice were primed by i.v.
injection of 5  105 DC.
Cell lines
MC57G are methylcholanthrene-induced fibrosarcoma cells of C57BL/6
origin. EL-4 are dimethylbenzanthrene-induced thymoma cells of
C57BL/6 origin. P815 are mastocytoma cells from BALB/c origin. BSC40
cells are a subclone of the green African monkey kidney cell line BSC-1.
NP118–126/Ld-specific and gp34–41/Kb-specific T cell hybridomas car-
rying the lacZ reporter construct were a kind gift from M. Groettrup (Uni-
versity of Constance, Constance, Germany). The NP118 hybridoma rec-
ognizes NP118–126 (RPQASGVYM) plus H-2Ld, the gp34 hybridoma
gp34–41 (AVYNFATC) plus H-2Kb (37, 38).
Peptide-specific CTL lines
Splenocytes from LCMV-WE memory mice (injected with 100 PFU
LCMV-WE at least 2 mo before) were restimulated with irradiated and
peptide-loaded (108 M), thioglycolate-elicited macrophages (1 ml of thio-
glycolate i.p. at day 3) at a ratio of 20:1 in the presence of 25 U/ml IL-2.
Cultures were restimulated every week as described above at a ratio of 5:1.
After three rounds of restimulation, CTL were found to be of single spec-
ificity. BALB/c memory CTL were restimulated with NP118–126
(RPQASGVYM, Ld) or with gp283–292 (GYCLTKWMIL, Kd) and
C57BL/6 memory CTL were restimulated with gp33–41 (KAVYNFATC,
Db), gp276–286 (SGVENPGGYCL, Db), or with NP396–404
(FQPQNGQFI, Db).
CTL assays
To measure direct ex vivo LCMV-specific CTL responses, splenocytes
were tested for cytolytic activity toward peptide-loaded (107 M) or un-
loaded 51Cr-labeled EL-4 or P815 target cells in a 5-h assay. The CTL
activity of LCMV-specific memory CTL was measured 5 days after in vitro
restimulation of splenocytes with peptide-loaded (108 M), irradiated, syn-
geneic thioglycolate macrophages (responder:stimulator  20:1) in the
presence of 25 U/ml IL-2. Standard dilutions of cultures were tested for
cytolytic activity on peptide-loaded 51Cr-labeled EL-4 or P815 cells in a
5-h assay.
Staining with tetrameric MHC class I-peptide complexes
Tetrameric complexes containing biotinylated H-2Db or H-2Ld, 2-micro-
globulin, the relevant peptide, and extravidin-PE were generated as de-
scribed previously (39, 40). Approximately 5 105 cells were stained with
0.5–1 g of tetramer in 25 l of FACS buffer (FB: PBS plus 2% FCS plus
0.01% NaN3 plus 20 mM EDTA) at 37oC for 10 min. One microliter of
anti-CD8-FITC (clone 53-6.7) was added and staining was continued for
30 min at 4oC. Cells were washed three times, fixed (FACS Lysis Solution;
BD Biosciences, Mountain View, CA) and were analyzed by flow cytom-
etry (FACScan; BD Biosciences) using CellQuest software. For tetramer
dissociation assays, cells were stained with tetramer as above, anti-CD8-
FITC, anti-CD4-biotin, anti-B220-biotin, and anti-I-Ab-biotin, for 30 min
at 4oC, were washed once, were stained with streptavidin-CyChrome for 20
min at 4oC (all BD PharMingen, San Diego, CA), and were washed three
times. Cells were suspended in 0.5 ml of FACS buffer containing pro-
pidium iodide and 150 g/ml mouse monoclonal IgG2a anti-Db (T21–460,
obtained from G. Ha¨mmerling, Deutsches Krebsforschungszentrum, Hei-
delberg, Germany) to prevent rebinding of dissociated tetramer at t  0.
Samples were incubated on ice for the indicated times and tetramer staining
was analyzed on CD8, CD4, B220, I-Ab, and propidium iodide-ve
cells. We measured the rate of decay using flow cytometry and we obtained
linear decay plots of the natural logarithm of the normalized fluorescence
vs time, indicating that tetramer dissociation was occurring stochastically
and that the resulting tetramer staining half-lives should be proportional to
the half-lives of the respective TCR-peptide-MHC complexes (41).
Intracellular cytokine staining (ICS) for IFN-
One million splenocytes were incubated in 200 l of IMDM plus 10% FCS
and antibiotics for 6 h at 37oC with 106 M of the specific peptide or with
medium alone as a negative control. To enhance intracellular accumulation
of IFN-, brefeldin A was added at a final concentration of 5 g/ml for the
whole duration of the culture. For staining, cells were put at 4oC, washed
with FACS buffer (FB, see above), and stained with anti-CD8-PE (BD
PharMingen) for 30 min at 4oC. Cells were washed twice with FB and fixed
with 100 l of 4% paraformaldehyde in PBS for 5 min at 4oC. Two mil-
liliters of permeabilization buffer (PB: FB plus 0.1% w/v saponin) were
added and cells were incubated for 10 min at 4oC. Cells were spun down
and stained intracellularly with anti-mouse-IFN--FITC (clone AN18; BD
PharMingen) in PB for 60 min at 4oC. After three washes with PB, cells
were resuspended in FB and analyzed by flow cytometry as described
above.
Kinetics of Ag presentation by LCMV-infected CB6F1
macrophages
Thioglycolate-elicited macrophages were isolated and infected with
LCMV-Arm or with LCMV-WE at a m.o.i. of 2 and were further incubated
at 37oC for the indicated times. Infected macrophages were harvested (t 
0) and brefeldin A was added to a final concentration of 5 g/ml to freeze
cells in their state of Ag presentation. The degree of infection was mea-
sured by intracellular staining for LCMV NP using FITC-labeled mono-
clonal rat-anti-LCMV NP (VL4 (42)), followed by FACS analysis. Mac-
rophages of the same batch were used as targets in a chromium release
assay and as stimulators in ICS using peptide-specific CTL lines as effec-
tors/responders. For these experiments, part of the macrophages were la-
beled with 51Cr (in the presence of brefeldin A) and were incubated with
titrated numbers of peptide-specific CTL in a 5-h Cr release assay in the
presence of brefeldin A. Another part of the macrophages was used as
stimulators of IFN- production in a 6-h ICS in the presence of brefeldin
A (3 105 macrophages plus 3 105 tetramer-positive CTL) as described
above. In the chromium release assay as well as in ICS, macrophages
loaded with titrated amounts of each of the five peptides (106–1012 M)
were included as a sensitivity control for the individual CTL lines.
Kinetics of Ag presentation by cells from LCMV-infected mice
CB6F1 mice were infected i.v. with 2  107 PFU of LCMV-WE. The high
inoculum size was chosen to ensure maximal numbers of infected cells in
the spleen. At defined time points after infection, spleens were homoge-
nized and used as APCs. Five 104 T cell hybridoma cells were incubated
overnight in 96-well round-bottom plates at 37oC with 1.5  105 spleno-
cytes from infected CB6F1 mice or with 1.5  105 naive CB6F1 spleno-
cytes with titrated amounts of the relevant antigenic peptide in 200 l of
medium containing 5 g/ml brefeldin A to freeze their condition of Ag
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presentation. After incubation, cultures were processed as described pre-
viously (43). Briefly, cells were washed with PBS and were subsequently
fixed with PBS containing 2% formaldehyde and 0.2% glutaraldehyde for
5 min at 4oC. The plates were washed with PBS and overlaid with 50 l
of staining solution (1 mg/ml 5-bromo-4-chloro-3-indolyl -D-galactoside,
5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and 2 mM
MgCl2 in PBS). T cell hybridomas that were stimulated through the TCR
can be visualized by blue staining, resulting from a lacZ reporter gene
under control of the IL-2 promoter/enhancer (37). Triplicate cultures were
microscopically examined, and the number of blue cells per well was
counted after overnight incubation at 37oC.
Measurement of virus titers
LCMV titers were determined in the spleens and livers at indicated time
points after infection. To determine LCMV titers, organs were removed,
homogenized in MEM/2% FCS, and titrated by 10-fold dilution onto
monolayers of MC57G cells in 24-well plates. LCMV was detected after 2
days of incubation at 37oC by an immunofocus assay using an LCMV
NP-specific mAb (VL4), as previously described (42). The detection limit
of this focus forming assay is 100 PFU/ml.
Results
Immunodominance is influenced by the LCMV inoculum and is
not related to T cell intrinsic features such as TCR affinity or
the capacity to expand
Since LCMV is a noncytopathic virus that replicates massively in
its natural host, the mouse, simple titration of the inoculum does
not cover a wide range of viral loads. To circumvent this problem
and to be able to analyze immunodominance at gradually increas-
ing viral loads, we took advantage of different viral isolates that are
known to have different replication rates, such that LCMV-Arm 
LCMV-WE  LCMV-Doc. We infected C57BL/6 mice with ti-
trated (10-fold dilutions) amounts of different LCMV strains and
measured virus titers 5 days later in the spleen. We then chose the
inoculum size to analyze immunodominance such that we had a
graded increase in viral load (see Fig. 1). We infected C57BL/6
mice with 102 or 106 PFU of LCMV-Arm, with 100, 102, or 106
PFU of LCMV-WE, or with 102 of 106 PFU of LCMV-Doc. The
viral load was measured in spleen at days 6, 8, and 15 (Fig. 1A,
upper panels) and in liver (comparable to spleen, data not shown)
and was found to increase in the following order: 102 PFU LCMV-
Arm 106 PFU LCMV-Arm 100 PFU LCMV-WE 102 PFU
LCMV-WE 102 PFU LCMV-Doc 106 PFU LCMV-WE 106
PFU LCMV-Doc. Virus was not detectable anymore at day 50 in
any of the mice, except for mice infected with 106 PFU LCMV-
Doc (50,000 PFU/spleen), which is in accordance with previously
published findings (20). Tetramer staining 15 days after infection
(Fig. 1A, middle panels) showed clear immunodominance of
NP396-CTL at low viral load, which gradually decreased with
increasing viral load. This resulted in immunodominance of gp33-
CTL at higher viral loads. Functional analysis of the CTL by ICS
ex vivo at day 15 after infection made the observed difference even
more clear (Fig. 1A, lower panels): At low viral load, NP396-CTL
were immunodominant, whereas they were functionally undetect-
able (although physically present to some extent) after infection
with 106 PFU LCMV-WE. In contrast, the number of gp33-CTL
increased at increasing viral load. High-dose (106 PFU) LCMV-
Doc resulted in such high amounts of rapidly spreading virus that
also gp-specific CTL were functionally and physically exhausted
(20, 40, 44), ultimately resulting in lifelong virus persistence. The
apparent higher sensitivity to exhaustion of NP-CTL might be ex-
plained by a lower naive precursor CTL (CTLp) frequency of NP-
CTL compared with gp-CTL; however, this possibility cannot ac-
count for the preferential priming of NP-CTL at low virus load.
The viral loads after infection with 106 PFU LCMV-Arm and 1
PFU LCMV-WE were apparently similar (Fig. 1A, upper panels);
however, the immunodominance profile was found to be different
(Fig. 1A, middle and lower panels). This is possibly attributable to
the fact that the resolution of the plaque assay is not sufficient to
detect small, but probably biologically relevant differences in viral
load immediately after infection. Moreover, analysis of the gp- and
NP-CTL response after infection of CB6F1 mice with 102 PFU
LCMV-Arm and 102 or 106 PFU LCMV-WE demonstrated that
the NP396- and the NP118-specific response behaved similarly
(i.e., going down upon increasing virus load) and opposite to the
gp33-specific response (i.e., increasing upon higher virus load)
(Fig. 1B). Because the NP118 response is a very strong one, se-
lective exhaustion of NP-CTL at high virus load is unlikely to
FIGURE 1. NP396-specific CTL are preferentially primed under con-
ditions of low viral load and are gradually exhausted as viral load increases.
A, C57BL/6 mice were infected with 100, 102, or 106 PFU of LCMV-Arm,
LCMV-WE, or LCMV-Doc. Upper panels, Viral titers were measured in
the spleen at indicated time points after infection. Middle panels, The phys-
ical presence of gp33- and NP396-CTL in the spleen was measured at day
15 after infection by tetramers. Lower panels, The functional presence of
gp33- and NP396-CTL in the spleen was measured at day 15 after infection
by ICS. The values are the mean of three mice; one representative exper-
iment of four is shown. B, CB6F1 mice were infected with 102 PFU of
LCMV-Arm and 102 or 106 PFU of LCMV-WE. Left panel, The physical
presence of gp33-, NP396-, and NP118-CTL in blood was measured at day
29 after infection by tetramers. Right panel, The functional presence in the
spleen was measured at day 29 after infection by ICS. The values represent
the mean of two mice; one experiment of two is shown. f, gp33; ,
NP396; , NP118.
5417The Journal of Immunology
result from low CTLp frequencies. The preferential priming of
NP-CTL at low viral load and their exhaustion upon increasing Ag
levels suggests that NP-CTL have somehow a higher sensitivity to
Ag than gp-CTL. We considered the possibility that CTL bearing
TCR with high affinity were preferentially activated at low virus
load and were more likely to be overstimulated and exhausted (18,
20) at higher virus load. As a consequence, we had to assume that
NP396-CTL generally have a TCR of higher affinity compared
with gp33-CTL. The most reliable manner to determine TCR af-
finities is probably by BiaCore; however, this method cannot be
applied on polyclonal T cell populations. Therefore, we used tet-
ramer dissociation on ex vivo-prepared CTL as a measure for the
TCR affinities of polyclonal, but mono-specific CTL populations
after infection with LCMV (41). We always included 318 TCR-
transgenic T cells that are specific for gp33/Db (29) as a reproduc-
ibility control. We found comparable tetramer dissociation kinetics
of gp33-CTL and of NP396-CTL after infection with LCMV (Fig.
2, A and B), suggesting no apparent difference in TCR affinity
between the two specificities. In addition, we found no difference
in TCR affinities between infection with LCMV-WE and -Arm
(Fig. 2, A and B). Also, by titrating peptides in ICS for IFN- or
on targets in a CTL assay, we did not find substantial differences
between gp33–41 and NP396–404 (data not shown) provided that
in these particular experiments we used the optimized Db binder
KAVYNFATM, with an affinity for Db comparable to NP396–
404, instead of the natural peptide KAVYNFATC. In addition,
when we used the natural peptide (KAVYNFATC) and corrected
for lower affinity to Db (12), we also did not see differences in
peptide titrations. The interaction of the TCR with H-2Db/
gp33–41 is not affected if the naturally occurring cysteine on po-
sition 9 is replaced by a methionine (45). Thus, the change of
immunodominance after infection with different amounts of virus
cannot be explained by differences in TCR affinity of polyclonal
NP396- and gp33-CTL populations.
To distinguish between factors intrinsic to the responding CTL
populations and LCMV-specific features, we primed mice with
5  105 bone marrow-derived DIETER DC transgenic for
gp33–41 and NP396–404 (30) and challenged them 10 days later
with 2  106 PFU rVV expressing gp33–41 or NP396–404 as a
minigene (VV33, VV396) or with 100 PFU LCMV-WE. We
found that gp33-CTL and NP396-CTL expanded to a similar ex-
tent after VV minigene challenge (Fig. 2C). In contrast, NP396-
CTL expanded considerably stronger than gp33-CTL after LCMV
challenge. This indicated that the difference in expansion seen in
LCMV-challenged mice is not an intrinsic property of the individ-
ual CTL populations but rather depends on LCMV as such.
LCMV-infected macrophages present LCMV NP-derived
CTL epitopes with increased kinetics compared with LCMV
gp-derived CTL epitopes
Using infected cells in vitro, it has been shown that the LCMV NP
is detectable at least 12 h before LCMV gp on the protein level
(28). Thus, NP-derived epitopes can be presented before gp-de-
rived epitopes, which may have important consequences for CTL
induction: NP-CTL will be primed before gp-CTL and they will
thus start controlling the virus before most gp-specific precursors
had the chance to interact with their nominal peptide on LCMV-
infected cells. Therefore, NP-CTL generally will be primed in the
face of higher viral load than gp-CTL and can interfere with prim-
ing of gp-CTL at the same time. We investigated the existence of
kinetic differences in the onset of presentation between gp-and
NP-derived epitopes by infecting thioglycolate-elicited CB6F1 (H-
2bxd) macrophages with LCMV-Arm or -WE at a m.o.i. of 2, re-
sulting in infection of 100% of the macrophages as demonstrated
by intracellular staining with an mAb against LCMV NP (VL4
(42)). Subsequently, their status of Ag presentation was frozen at
different time points after infection by brefeldin A, and these mac-
rophages were used as stimulators for IFN- production (ICS) by
mono-specific CTL lines specific for three gp-derived (gp33–41/
Db, gp276–286/Db, gp283–292/Kd) and two NP-derived (NP118–
126/Ld, NP396–404/Db) epitopes. We found that gp-derived
epitopes were detectable by CTL after 7–8 h of infection and
reached their maximum after 10 h, whereas NP-derived epitopes
reached their maximum around 2 h after infection (Fig. 3). This
was true for both LCMV-Arm (Fig. 3, left panels) and -WE (Fig.
3, middle panels), excluding the possibility that differences in im-
munodominance seen in vivo after infection with LCMV-Arm
(NP396 immunodominant) or -WE (gp33 immunodominant) were
due to differences in Ag processing or presentation between the
two LCMV strains. Because differences in Ag sensitivity between
the individual CTL lines would obscure our data, we included
CB6F1 macrophages loaded with titrated amounts of peptide in the
same experiment to check the Ag sensitivity of CTL lines. Half-
maximal stimulation of IFN- production required 1010 M gp33,
FIGURE 2. gp33- and NP396-specific CTL show similar TCR affinity
as measured by tetramer dissociation rates and are not intrinsically different
with respect to their ability to expand in vivo. C57BL/6 mice were infected
i.v. with 102 PFU of LCMV-Arm or -WE, and splenocytes were stained
with tetramer as described in Materials and Methods 35 days later. Tet-
ramer-stained cells were incubated on ice for the indicated times in the
presence of saturating amounts of a monoclonal anti-Db Ab to prevent
rebinding of dissociated tetramer as described elsewhere (41). The disso-
ciation of tetramers was measured by FACS. A, Representative decay plots
of one LCMV-Arm- and one LCMV-WE-infected mouse. Decay plots
show the natural logarithm of the normalized fluorescence vs time. B, The
mean of calculated half-lives of TCR-peptide-H-2Db interaction of three
individual mice is plotted. C, C57BL/6 mice were primed with 5  105
syngeneic DIETER DC transgenic for gp33 and NP396 (30) and were
challenged 10 days later with 2  106 PFU of VV33, 2  106 PFU of
VV396, or with 102 PFU of LCMV-WE. Expansion of gp33- and of
NP396-CTL was measured in the blood by tetramers 8 days after chal-
lenge. Results represent the mean of two individual mice, and one repre-
sentative experiment of two is shown.
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1011 M gp276, between 109 and 1010 M NP396, and 108M
NP118 (Fig. 3, right panels). This indicates that gp-CTL lines were
slightly more sensitive to Ag compared with the NP-CTL lines,
excluding that faster detection of NP epitopes was due to higher
Ag sensitivity of NP-CTL lines. However, the gp283-CTL line
appeared relatively Ag insensitive (107 M required) and
gp283–292 also became detectable extremely late (8.5 h) after in-
fection (Fig. 3). This may be explained by the fact that CB6F1
macrophages express limited numbers of the gp283–292-present-
ing H-2Kd molecule, whereas substantially higher numbers of
H-2Db and H-2Ld are expressed (data not shown). Using the same
macrophages (infected for different times with LCMV-Arm or
-WE or loaded with titrated peptide) as targets for peptide-specific
CTL lines in a 5-h 51Cr release assay, the above-mentioned kinetic
differences were confirmed: NP-CTL lines (data not shown).
LCMV-infected splenocytes ex vivo present LCMV NP-derived
CTL epitopes with increased kinetics compared with LCMV
gp-derived CTL epitopes
LCMV is known to infect a variety of cells in vivo, such as DC and
macrophages (46), and, therefore, in vitro-infected, thioglycolate-
elicited macrophages may not represent the physiologically rele-
vant population presenting LCMV-derived epitopes in vivo. To
analyze the kinetics of Ag presentation in vivo, we infected CB6F1
mice with 2  107 PFU LCMV-WE and used their splenocytes at
different time points after infection as APC for NP118–126/Ld- or
gp34–41/Kb-specific T cell hybridomas (38, 43). To exclude the
possibility that differences in Ag sensitivity between the two hy-
bridomas would influence our result, we included uninfected
CB6F1 macrophages with titrated amounts of peptide in the same
experiment. For both hybridomas, maximal numbers of blue cells
were found at 107 M peptide or higher and background numbers
were found below 1010 M peptide. This shows that the gp34/Kb-
specific and the NP11/Ld-specific hybridoma were equally sensi-
tive to Ag.
The kinetics of Ag presentation by in vivo-infected splenocytes
were similar to those by in vitro-infected, thioglycolate-elicited
macrophages (Fig. 4). gp34-specific T cells were activated by
splenocytes that were infected for 12 h or more, and splenocyte
infection for 20 h or more induced maximal numbers. In contrast,
infection of splenocytes for 4 h or more resulted in the presentation
of the NP118 epitope and maximal levels were reached after 12 h.
The maximal numbers of activated hybridomas after incubation
with infected splenocytes were 50% of the maximal values ob-
served after incubation with peptide in both cases. This may be
explained by the fact that peptides were present throughout the
overnight culture, thus avoiding the influence of peptide off-rates
as is the case with infected splenocytes in the presence of
brefeldin A.
Presentation by in vivo-infected splenocytes displayed a delay
of 2 h for both epitopes (NP and gp derived) compared with the
in vitro-infected macrophages (Fig. 3). This may be explained by
the lower peptide sensitivity of the hybridomas (108 M (64))
compared with the mono-specific CTL lines we used (Fig. 3) or by
the fact that it takes LCMV slightly longer to infect cells in vivo
than in vitro, where the cells were infected at a high m.o.i. and in
very close contact with the virus.
Kinetic differences in the presentation of LCMV-derived CTL
epitopes can be visualized in vivo
To show the relevance of faster kinetics of presentation of NP-
derived epitopes in vivo, we designed the following experiment:
FIGURE 3. NP-derived CTL epitopes are presented to CTL with faster
kinetics than gp-derived CTL epitopes. Thioglycolate-elicited CB6F1 mac-
rophages were infected with LCMV-Arm (left panels) or LCMV-WE (mid-
dle panels) with a m.o.i. of 2, and the state of Ag presentation was frozen
at indicated time points by addition of brefeldin A (5 g/ml). Subse-
quently, these macrophages were used to induce IFN- production by five
independent, peptide-specific CTL lines as a readout. CTL were incubated
with infected macrophages in the presence of brefeldin A for 6 h and were
surface stained for CD8 and intracellularly for IFN-. Right panels, The
same CTL lines were incubated as described above with CB6F1 macro-
phages loaded with titrated amounts of peptide to determine the peptide
sensitivity of the individual CTL lines. One representative experiment of
four is shown.
FIGURE 4. LCMV-infected splenocytes ex vivo present LCMV NP-
derived CTL epitopes with increased kinetics compared with LCMV gp-
derived CTL epitopes. CB6F1 mice were infected i.v. with 2 107 PFU of
LCMV-WE, their splenocytes were isolated at different time points after
infection and were used as APC for NP118–126/Ld- or for gp34–41/Kb-
specific T cell hybridomas. Five  104 T cell hybridomas were incubated
overnight at 37oC with 1.5  105 LCMV-infected splenocytes (left panels)
or with 1.5  105 uninfected splenocytes in the presence of titrated
amounts of peptide (right panels). Five micrograms of brefeldin A per
milliliter was present throughout the culture period to freeze the status of
Ag presentation by the infected splenocytes. After stimulation through the
TCR, T cell hybridomas can be visualized by blue staining, resulting from
a lacZ reporter gene under control of the IL-2 promoter/enhancer (37).
Cultures were microscopically examined, and the number of blue cells per
well was counted. Values represent the mean 	 SD of triplicate cultures.
One mouse was used per time point of infection. One representative ex-
periment of two is shown.
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We reasoned that “early” memory CTL (e.g., NP-CTL) recognize
infected cells and start to eliminate them before “late” CTL (e.g.,
gp-CTL) had the chance to interact with their Ag, and thus sub-
stantially interfere with the priming of the latter. As a conse-
quence, early memory CTL (e.g., NP-CTL) should block priming
of late CTL (e.g., gp-CTL) upon infection with LCMV, but not
vice versa. Thus, we primed mice with VV33, VV396, or VVc and
challenged them 30 days later with 100 PFU LCMV-WE to in-
vestigate whether we could prime gp-CTL in the face of a pre-
existing NP-CTL memory response and vice versa. It is important
to note that priming with VV33 or with VV396 protects mice
against subsequent LCMV challenge, resulting in very low (unde-
tectable) LCMV levels (data not shown). We measured the fre-
quency of gp33- and NP396-CTL in the spleen by tetramer stain-
ing (Fig. 5) at day 9 after LCMV challenge and confirmed the data
by a primary ex vivo CTL assay 9 days after LCMV infection (data
not shown).
After VV396 priming, pre-existing memory NP396-CTL were
found to expand massively upon LCMV challenge (Fig. 5). gp33-
CTL were not primed by LCMV in the presence of memory
NP396-CTL (Fig. 5). This can be explained by different kinetics of
Ag presentation: NP396-CTL could start to control LCMV-in-
fected cells before gp33-CTL could efficiently interact with them,
resulting in inhibition of gp33-CTL priming. In the reverse situa-
tion, VV33 priming results in enhanced expansion of gp33-CTL
after LCMV challenge compared with VVc priming, thus demon-
strating the increased number of gp33-specific precursors due to
VV33 priming (Fig. 5). Interestingly, and in contrast with the sit-
uation described above, pre-existing memory gp33-CTL did not
interfere with the priming of NP396-CTL (cf VVc and VV33 in
Fig. 5). This shows that gp33-CTL, even although present as mem-
ory cells and at increased CTLp numbers, could not interfere with
the priming of NP396-CTL. Because gp is presented with delayed
kinetics compared with NP, gp33-CTL were too late to interfere
with NP396-CTL priming. The ex vivo CTL assay performed on
day 9 confirmed the tetramer data (data not shown). It is unlikely
that differences in priming between VV33 and VV396 are respon-
sible for the observed findings: Priming with VV33 or with VV396
resulted in a specific CTL response of similar size as deter-
mined by tetramer analysis (0.8 –1.0% of the CD8 at day 10
after infection) and by limiting dilution analysis (1 in 104
splenocytes at day 7 after infection). The frequency of specific
memory CTL was comparable for VV33- and VV396-infected
mice over at least 5 wk as measured by protection against
LCMV challenge (data not shown).
Discussion
LCMV infection induces a protective CTL response against both
gp- and NP-derived epitopes. We describe here that inocula lead-
ing to a relatively low virus load (e.g., LCMV-Arm) resulted in
immunodominance of NP-CTL, whereas increasing viral load
(e.g., LCMV-WE or -Doc) coincided with decreasing NP-CTL,
ultimately resulting in immunodominance of gp-CTL. We ex-
plained this finding by a higher sensitivity to Ag of NP-CTL com-
pared with gp-CTL: NP-CTL thus would be preferentially acti-
vated by low levels of Ag and (partially) exhausted (18, 20, 44)
upon increasing viral load. It has been suggested (46) that different
strains of LCMV infect different cells in vivo: this would preclude
comparison between strains as we do here. We infected C57BL/6
mice with 106 PFU of LCMV-Arm, -WE, or -Doc and stained
splenocytes for subset markers and LCMV NP. We found that,
independent of the strain used to infect, 5–8% of CD11c, 0.7–
1.5% of CD11b, and0.5% of CD19 or TCR cells stained
positive for LCMV NP. This excludes that changes in immu-
nodominance were due to different tropism of the individual
strains. Comparison of the gp33- and the NP396-specific CTL re-
sponse after infection with 1 or with 100 PFU of LCMV-WE dem-
onstrates that the gp33-specific response increased, whereas the
NP396 response decreased with higher viral load (Fig. 1). The data
of Ou et al. (44) can be interpreted along the same line: They
showed that infection of mice deficient for the IFN- receptor
(A129 mice) with 100 PFU of LCMV-WE or with 105 PFU of
LCMV-Arm resulted in a substantially higher viral load and in
selective exhaustion of NP396-CTL when compared with wild-
type control mice. Thus, also without varying the virus strain/dose
used for infection, but by choosing the conditions such that the
virus replicates to higher titers, NP-CTL were found to gradually
disappear. We considered that the higher Ag sensitivity of NP-
CTL could be due to 1) higher TCR affinity of NP-CTL, 2) pro-
longed presentation of NP compared with gp by infected cells (47),
or 3) different kinetics of presentation of NP vs gp epitopes (28).
We found no difference in TCR affinity as measured by tetramer
dissociation (41) between NP396- and gp33-CTL or by peptide
titration in CTL assay and in ICS. The finding that in mice per-
sistently infected with LCMV gp expression was not found after
day 15, whereas NP could be detected in all mice even after 80
days, has been used to explain the relatively high sensitivity to
overstimulation of NP-CTL (18). However, the prolonged pres-
ence of a stable protein, like NP, does not mean that CTL epitopes
are generated continuously: It has been proposed by Yewdell et al.
(48) that the majority of the MHC class I-binding peptides are
derived from defective ribosomal products and thus heavily de-
pend on protein neosynthesis. Two studies supported this hypoth-
esis (49, 50), and we showed recently for LCMV NP that no CTL
epitopes were generated from this long-lived protein, unless neo-
synthesis took place (51). Therefore, the relevance of the obser-
vation that gp is not as persistent as NP in chronically infected
mice to (over)stimulation of NP-CTL is not certain. We cannot
formally exclude the possible contribution of cross-priming to the
phenomenon we describe here. However, we do not expect cross-
priming to be an important pathway for priming a CTL response
against a pathogen that very efficiently infects DC.
We analyzed the kinetics of presentation of NP- and of gp-
derived epitopes by LCMV-WE- and -Arm-infected macrophages,
because we argued that faster presentation of NP-derived epitopes
could account for a better protective capacity on a per cell basis
FIGURE 5. NP396-specific memory inhibits priming of gp33-specific
cells, but not vice versa. C57BL/6 mice were primed by i.p. injection of
2  106 PFU of rVV33, rVV396, or rVVc and challenged 30 days later
with 102 PFU of LCMV-WE. The expansion of gp33- and NP396-CTL
was measured in the blood by tetramer staining after 9 days. Results rep-
resent the mean of three individual mice. One representative experiment of
three is shown.
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(19), for better priming at limited viral load, and for higher sen-
sitivity to exhaustion at high viral load. We found that, indepen-
dent of the LCMV strain used, both NP-derived epitopes were
sufficiently presented to stimulate CTL as early as 2.5 h after in-
fection, whereas it took at least 8 h before three different gp-de-
rived epitopes were recognized. It is unlikely that different travel-
ing times of particular MHC class I molecules from the
endoplasmic reticulum to the cell surface account for the kinetic
differences observed here, as H-2Db is the restricting element of
one NP-derived and two gp-derived peptides. To formally exclude
the possibility that in vitro-infected, thioglycolate-elicited macro-
phages differed with respect to Ag presentation from those cells
that are naturally infected by LCMV in vivo, we used splenocytes
isolated from LCMV-infected mice at different time points after
infection as APC to stimulate gp- or NP-specific T cell hybridomas
(37, 38, 43). Using this approach, we found similar kinetic differ-
ences between the presentation of gp- and NP-derived epitopes.
We used above readouts for Ag presentation rather than peptide
elution from MHC class I molecules, because the latter method
requires a large amount of cells (5  108 per time point and
virus) that is impossible to obtain from other sources than from cell
lines, the latter being probably abnormal in Ag processing or
presentation.
As a result of faster kinetics of NP presentation, NP-CTL en-
counter their nominal peptide on every infected cell before gp-
CTL do and will therefore be activated earlier and probably in the
face of higher viral loads. The consequences of delayed gp pre-
sentation were demonstrated in vivo: pre-existing memory NP-
CTL inhibited priming of gp-CTL, whereas pre-existing memory
gp-CTL did not interfere with NP-CTL priming. In an attempt to
investigate consequences of kinetic differences in epitope presen-
tation for in vivo priming in a direct manner, we analyzed the
expansion kinetics of NP- and gp-specific CTL at different early
time points after infection. To this end, we performed ICS at 3, 4,
5, 6, 7, 8, and 9 days after infection. We detected LCMV-specific
CTL from day 5 onward; however, we did not find substantial
differences in expansion kinetics of NP- vs gp-CTL (data not
shown). Detection of specific CTL by tetramers was unreliable as
long as virus was still present (approximately until day 7), prob-
ably due to TCR down-regulation. Kinetic differences of 8 h may
not lead to detectable differences in expansion kinetics, because
the time required for initial T cell activation and proliferation is
much longer than 8 h, thus masking possible initial differences.
Moreover, it may well be that possible differences in expansion
kinetics could not be detected anymore by day 5 because most of
the virus usually is eliminated by then and a substantial part of the
NP-CTL may be exhausted before they could expand to numbers
that allow detection. No comparative data on naive CTLp frequen-
cies are currently available. Alternatively, small differences in the
frequencies of CTLp could probably cover up differences in ex-
pansion kinetics.
Kinetic differences in epitope presentation may also explain the
finding that a NP118-CTL escape mutant of LCMV, that still ex-
pressed the gp283 CTL epitope, was controlled slower than the
wild-type virus in BALB/c mice, but equally fast in CB6F1 mice
(that could use an additional NP-derived epitope, NP396) (13). It
was found in the same study that the 118-CTL escape mutant ef-
ficiently primed subdominant gp283-CTL in BALB/c mice, but not
in CB6F1 mice, whereas LCMV-WE did not prime gp283-CTL in
either mouse strain: Absence of an early NP-specific response in
BALB/c mice (but not in CB6F1 mice) results in slower virus
control and allows the priming of otherwise subdominant and later
gp-specific responses. Results obtained by mathematical analysis
of the LCMV-specific CTL response in BALB/c mice (52) can
also be explained by kinetic differences in epitope generation.
Based on our findings, we propose the general rule that CTL
against early epitopes normally clear most of the virus and are at
risk to be exhausted if the initial viral load is relatively high. Ex-
periments showing that early NP-CTL are 100 times more effective
in protecting mice against LCMV compared with late gp-CTL
(Ref. 19 and M. F. van den Broek and H. C. Probst, unpublished
data) fit this hypothesis. Data on specific CTL responses in other
viral infections than LCMV seem to support the general applica-
bility of our hypothesis. Vaccination of macaques with early sim-
ian immunodeficiency virus proteins (Rev, Tat) induced a protec-
tive immunity that was substantially more effective than
vaccination with late simian immunodeficiency virus proteins (Pol,
Gag) (53). Along the same line, longitudinal analysis of the HIV-
specific CTL response in individuals with a high HIV load re-
vealed that Rev- and Tat-specific CTL were the first to disappear
(54–56). In analogy to what we described here for LCMV infec-
tion, namely, evidence for early activation of specific CTL fol-
lowed by their gradual functional or even physical disappearance
after they were unable to eliminate the Ag in due time can be found
in a variety of infections, such as HIV (57, 58), hepatitis B (59–
61), and hepatitis C (62) and also in tumor-bearing patients (63).
We propose that CTL against early viral proteins swiftly inter-
fere with virus replication, resulting in efficient protection. If these
early CTL fail in immediate virus control, they are activated in the
face of higher viral load compared with late CTL and are therefore
prone to be exhausted.
Thus, the observed absence of CTL in persistent infections might
not be the cause, but rather the consequence of viral persistence.
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